Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"

Nast, Alexander; Augustin, Matthias; Boehncke, Wolf-Henning; Klaus, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Sebastian, Michael; Sterry, Wolfram; Streit, Volker; Weisenseel, Peter; Rzany, Berthold

doi:10.1111/j.1610-0387.2009.07312_supp.x

Scientific article

English

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"

ContributorsNast, Alexander; Augustin, Matthias; Boehncke, Wolf-Henning; Klaus, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Sebastian, Michael; Sterry, Wolfram; Streit, Volker; Weisenseel, Peter; Rzany, Berthold

Published inJournal der Deutschen Dermatologischen Gesellschaft, vol. 8, no. 1, p. 65-66

Publication date2010

Abstract

In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

Keywords

Antibodies, Monoclonal/adverse effects/*therapeutic use
Dermatology/*standards
European Union
*Evidence-Based Medicine
Humans
*Practice Guidelines as Topic
Psoriasis/*drug therapy

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

NAST, Alexander et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: ‘Therapeutic options’ and ‘Efalizumab’. In: Journal der Deutschen Dermatologischen Gesellschaft, 2010, vol. 8, n° 1, p. 65–66. doi: 10.1111/j.1610-0387.2009.07312_supp.x

Article

Identifiers

PID : unige:29866
DOI : 10.1111/j.1610-0387.2009.07312_supp.x
PMID : 20096063

Additional URL for this publicationhttp://onlinelibrary.wiley.com/store/10.1111/j.1610-0387.2009.07312_supp.x/asset/j.1610-0387.2009.07312_supp.x.pdf?v=1&t=hkp754nx&s=99a8fd1617dfa88d04259d4643479a9f9eee0a20

Journal ISSN1610-0379

629views

0downloads

Creation20/09/2013 16:48:59

First validation20/09/2013 16:48:59

Update14/03/2023 20:26:15

Status update14/03/2023 20:26:14

Last indexation30/10/2024 14:30:43

Archive ouverte UNIGE

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"

Technical informations